Alzheon, Inc.

Member

Alzheon, Inc. a clinical-stage biopharmaceutical company developing a portfolio of product candidates and diagnostic assays for patients living with Alzheimer’s disease (AD) and related neurodegenerative disorders. ALZ-801 (valiltramiprosate) is an investigational oral agent in Phase 3 development as a potentially disease modifying treatment for AD. It is designed to block the formation of neurotoxic soluble beta amyloid oligomers causing cognitive decline in Alzheimer’s patients. For more information, please visit: https://alzheon.com/